Hints and tips:
Related Special Reports
...Pfizer will also have the opportunity to sell out of its consumer health joint venture with GlaxoSmithKline when it lists in London as Haleon this summer....
...before molnupiravir,” said Daina Graybosch, analyst at SVB Leerink, citing Paxlovid, Gilead Sciences’ remdesivir — an antiviral administered via injection — and monoclonal antibody therapy sotrovimab from GlaxoSmithKline...
...Haleon, GlaxoSmithKline’s consumer healthcare venture with Pfizer, is down about 5 per cent from its July listing price....
...BMS is one of several large pharmaceutical companies, including Pfizer and GlaxoSmithKline, that are aiming to bolster their pipelines as some of their blockbuster drugs come off patent....
...Pfizer will sell down its stake in Haleon, its consumer health joint venture with GlaxoSmithKline, after a London listing planned for July 18....
...CureVac, another German mRNA vaccine maker, is also hoping to enter the flu market with its partner GlaxoSmithKline....
...It is the latest blow for Unilever, which has been under fire from investors over its languishing share price and a failed bid for GlaxoSmithKline’s consumer health division....
...Smart reads Dwindling dynasties The generation that built Japan Inc is running out of heirs, as the country’s rapidly shrinking population creates a national succession crisis and ample opportunity for...
...Health experts said the declining effectiveness of the two most commonly used antibody treatments has led to shortages of a third monoclonal antibody treatment sotrovimab, which is made by GlaxoSmithKline...
...Pfizer and BioNTech are teaming up to develop a messenger RNA vaccine for shingles, competing with GlaxoSmithKline’s flagship vaccine for the painful disease that mainly hits older people....
...GlaxoSmithKline and Pfizer are holding out for an improved bid of at least £60bn for their consumer healthcare joint venture, bolstered by shareholder opposition to Unilever’s £50bn offer....
...GlaxoSmithKline has rejected a £50bn bid from Unilever to acquire its consumer health joint venture with Pfizer, saying it “fundamentally undervalued” the business and its future prospects....
...CureVac, a German biotech that has yet to have a Covid vaccine approved, is also hoping to enter the flu market, with its partner UK drugmaker GlaxoSmithKline....
...The only Covid treatments approved outside hospital settings in the US are monoclonal antibodies developed by Regeneron, Eli Lilly and GlaxoSmithKline, which are typically given via intravenous infusions...
...Merck’s news hit shares in vaccine makers such as Moderna and BioNTech, as well as Vir Biotechnology, developer of a monoclonal antibody therapy in partnership with GlaxoSmithKline....
...As tensions between London and Brussels over vaccine supplies escalated earlier this year, Britain struck an agreement with GlaxoSmithKline to contribute to the manufacture of the Novavax doses bought by...
...So far, the only treatments approved for mild to moderate Covid are expensive monoclonal antibodies developed by Regeneron, Eli Lilly and GlaxoSmithKline, which are typically given intravenously....
...But it faces tough competition from Procter & Gamble, GlaxoSmithKline’s consumer business, which is also spinning off from its group, and a wave of smaller companies tapping into demand for organic and natural...
...their defeated leader, Republican politicians have continued to promote the use of monoclonal antibodies, laboratory-made versions of the body’s natural defences that are also produced by Eli Lilly and GlaxoSmithKline...
...The world’s biggest vaccine makers GlaxoSmithKline, Merck and Sanofi have all failed to deliver Covid jabs at all....
...Medicago, which is partnering with GlaxoSmithKline for its adjuvant, is analysing phase 3 trial data for the Covid vaccine involving 24,000 subjects in Canada, the US, UK, Brazil, Argentina and Mexico....
...Carlyle, which last year appointed former GlaxoSmithKline chief financial officer Simon Dingemans to oversee European healthcare deals, had kept its own offer on the table last month even after saying it...
...So far, the only Covid-19 treatments approved outside hospital settings in the US are monoclonal antibodies developed by Regeneron, Eli Lilly and GlaxoSmithKline, which are typically given via intravenous...
...This month, GlaxoSmithKline’s RTS,S jab finally won World Health Organization approval....
...Shares in Vectura, whose clients include GlaxoSmithKline and Hikma Pharmaceuticals, closed up 14 per cent at 155p....
International Edition